Date | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) |
---|
CEO | Mr. Wennian Wu |
IPO Date | June 16, 2020 |
Location | China |
Headquarters | No. 182, Beijing Road |
Employees | 672 |
Sector | Health Care |
Industries |
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.
Past 5 years
USD 8.51
USD 3.37
USD 3.45
USD 4.00
USD 9.47
StockViz Staff
January 15, 2025
Any question? Send us an email